Scarica l'app Stockscreener
80.99
2.45%
1.94
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EW Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$79.05
Aprire:
$78.79
Volume 24 ore:
5.55M
Relative Volume:
1.17
Capitalizzazione di mercato:
$46.69B
Reddito:
$6.07B
Utile/perdita netta:
$1.06B
Rapporto P/E:
44.84
EPS:
1.8063
Flusso di cassa netto:
$1.34B
1 W Prestazione:
+4.01%
1M Prestazione:
-3.89%
6M Prestazione:
+8.51%
1 anno Prestazione:
+13.23%
Intervallo 1D:
$78.79
$81.69
Intervallo di 1 settimana:
$77.10
$81.69
Portata 52W:
$68.63
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Nome
Edwards Lifesciences Corp
Settore
Industria
Telefono
(949) 250-2500
Indirizzo
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
80.99 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
ABT
Abbott Laboratories
|
96.81 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
343.32 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.19 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.23 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-01 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2025-12-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-10-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2025-04-24 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Aggiornamento | Stifel | Hold → Buy |
| 2025-01-16 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Downgrade | Jefferies | Buy → Hold |
| 2024-07-31 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-07-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Downgrade | TD Cowen | Buy → Hold |
| 2024-07-25 | Downgrade | Truist | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-05-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-02-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-28 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-03-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Downgrade | Bernstein | Outperform → Underperform |
| 2023-01-30 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Downgrade | Stifel | Buy → Hold |
| 2022-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Iniziato | Mizuho | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-29 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Iniziato | Truist | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-27 | Reiterato | Citigroup | Buy |
| 2022-01-27 | Reiterato | Evercore ISI | Outperform |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | Stifel | Buy |
| 2022-01-27 | Reiterato | UBS | Neutral |
| 2021-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-30 | Reiterato | Deutsche Bank | Hold |
| 2021-07-30 | Reiterato | Jefferies | Buy |
| 2021-07-30 | Reiterato | Morgan Stanley | Overweight |
| 2021-07-30 | Reiterato | Oppenheimer | Outperform |
| 2021-07-30 | Reiterato | Stifel | Buy |
| 2021-07-30 | Reiterato | UBS | Neutral |
| 2021-07-30 | Reiterato | Wells Fargo | Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-04-05 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-11 | Reiterato | Canaccord Genuity | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Underperform |
| 2020-04-28 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Outperform |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-09-23 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-24 | Reiterato | BofA/Merrill | Buy |
| 2019-03-18 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Hold |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-10-02 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Downgrade | Guggenheim | Buy → Neutral |
Mostra tutto
Edwards Lifesciences Corp Borsa (EW) Ultime notizie
Birch Hill Investment Advisors LLC Sells 13,385 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. Experiences Valuation Adjustment Amidst Market Dynamics and Performance Metrics - Markets Mojo
Edwards Lifesciences Corporation $EW Shares Sold by Ninety One UK Ltd - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
TD Cowen reiterates Edwards Lifesciences stock rating on TAVR strength By Investing.com - Investing.com South Africa
TD Cowen reiterates Edwards Lifesciences stock rating on TAVR strength - Investing.com
KBC Group NV Reduces Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Fisher Funds Management LTD Decreases Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026 - marketscreener.com
Edwards Lifesciences Corporation $EW Stock Position Lessened by Diversify Advisory Services LLC - MarketBeat
Edwards Lifesciences Hits Day Low of $79.06 Amid Price Pressure - Markets Mojo
EW Technical Analysis | Trend, Signals & Chart Patterns | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences (EW) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Hardman Johnston Global Advisors LLC Sells 34,124 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Growth Report: Will Edwards Lifesciences Corporation outperform its industry peersWatch List & Fast Moving Stock Watchlists - baoquankhu1.vn
Edwards Lifesciences’ CFO Ullem sells $1m in shares - Investing.com UK
Edwards Lifesciences Corp (EW) Stock Down 3.1% -- Now Undervalued? GF Score: 98/100 - GuruFocus
Edwards Lifesciences (NYSE: EW) CFO trades 13K shares under 10b5-1 plan - Stock Titan
Edwards Lifesciences Tops $430 Million Daily Turnover Amid Earnings Miss and Valuation Squeeze - Bitget
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards Lifesciences Corp. stock rises Wednesday, still underperforms market - MarketWatch
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $97 From $95, Maintains Buy Rating - marketscreener.com
Sivik Global Healthcare LLC Acquires New Shares in Edwards Lifesciences Corporation $EW - MarketBeat
Rathbones Group PLC Has $1.42 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
Edwards Lifesciences CVP Lippis sells $82,522 in stock - Investing.com
Edwards Lifesciences (EW) CVP exercises options and sells 1,019 shares under 10b5-1 plan - Stock Titan
Edwards Lifesciences (EW) Sees Analyst Rating Maintain with Targ - GuruFocus
Edwards Lifesciences price target lowered to $92 from $94 at Evercore ISI - TipRanks
Nvwm LLC Has $1.46 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Edwards Lifesciences Corporation (EW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Donald Bobo Jr Sells 22,680 Shares of Edwards Lifesciences (NYSE:EW) Stock - marketbeat.com
Edwards Lifesciences (EW) VP sells 22,680 shares after option exercise - Stock Titan
EW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EW PE Ratio & Valuation, Is EW Overvalued - intellectia.ai
Edwards Lifesciences Corporation $EW Shares Acquired by J. Safra Sarasin Holding AG - MarketBeat
Assessing Edwards Lifesciences (EW) Valuation As Growth Hopes Contrast With Rich P/E Multiple - finance.yahoo.com
Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits - BioSpace
Edwards Lifesciences Hits Day Low of $78.58 Amid Price Pressure - Markets Mojo
Edwards Lifesciences Corp (EW) Shares Gap Down to $79.34 on Mar 30 - GuruFocus
Edwards Lifesciences Announces New Data on EVOQUE Transcatheter Tricuspid Valve Replacement System - marketscreener.com
Is Edwards Lifesciences (EW) Pricing Look Attractive After Recent Pullback? - simplywall.st
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
What to Expect From Edwards Lifesciences' Next Quarterly Earnings Report - Barchart.com
Edwards Lifesciences Corp (EW) Shares Down 3.61% on Mar 27 - GuruFocus
Vanguard affiliate reports zero holdings in Edwards Lifesciences (NYSE: EW) - Stock Titan
[DEF 14A] Edwards Lifesciences Corp Definitive Proxy Statement - Stock Titan
SG Americas Securities LLC Grows Stock Position in Edwards Lifesciences Corporation $EW - marketbeat.com
Edwards Lifesciences Corp Azioni (EW) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):